PDF herunterladen
Semin Thromb Hemost 2008; 34(6): 509-519
DOI: 10.1055/s-0028-1103362
© Thieme Medical Publishers

Genetics of Bleeding Disorders in Women

Enrico M. Novelli1 , Margaret V. Ragni1
  • 1Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh School of Medicine, and The Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
28. November 2008 (online)

    Lizenzen und Reprints

ABSTRACT

With the strides being made in the European, Canadian, and American prospective studies of von Willebrand disease (VWD) genotype and phenotype, genetics is increasingly playing a key role in the classification, understanding, and management of VWD. It is anticipated that as gene sequencing becomes easier and more commonplace and the relationship between genotype and clinical and laboratory phenotype becomes clearer, genetic analysis will assume an increasingly important role in diagnosis, prediction of clinical severity, response to hemostatic agents, and optimal individualized management. This is an evolving field, so the reader is urged to stay tuned as new information becomes available, as it will likely change how individuals with bleeding disorders are managed. The purpose of this article is to review the genetics of inherited bleeding disorders in women, focusing on bleeding manifestations, diagnostic methodologies, and management.

KEYWORDS

Bleeding disorders - VWD - genetic testing - genotype - menorrhagia - bleeding severity score

REFERENCES

  • 1 Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease.  Blood. 1987;  69 454-459
    PubMedGoogle Scholar
  • 2 Mancuso D J, Tuley E A, Westfield L A et al.. Structure of the gene for human von Willebrand factor.  J Biol Chem. 1989;  264 19514-19527
    PubMedGoogle Scholar
  • 3 Sadler J E, Budde U, Eikenboom J C et al.. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.  J Thromb Haemost. 2006;  4 2103-2114
    CrossrefPubMedGoogle Scholar
  • 4 James A H. More than menorrhagia: a review of the obstetric and gynaecological manifestations of von Willebrand disease.  Thromb Res. 2007;  120(Suppl 1) S17-S20
    CrossrefPubMedGoogle Scholar
  • 5 James P D, Notley C, Hegadorn C et al.. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study.  Blood. 2007;  109 145-154
    CrossrefPubMedGoogle Scholar
  • 6 Goodeve A, Eikenboom J, Castaman G et al.. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD).  Blood. 2007;  109 112-121
    CrossrefPubMedGoogle Scholar
  • 7 Bellissimo D B, Christopherson P A, Haberichter S L et al.. Novel VWF sequence variations identified in normal controls and index cases enrolled in the TS Zimmerman Program for the Molecular and Clinical Biology of VWD (ZPMCB-VWD).  Blood. 2007;  110 709 (a218)
    PubMedGoogle Scholar
  • 8 Rodeghiero F, Castaman G, Tosetto A et al.. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study.  , [see comment][erratum appears in J Thromb Haemost 2006;4(4):925] J Thromb Haemost. 2005;  3 2619-2626
    CrossrefPubMedGoogle Scholar
  • 9 Haberichter S L, Christopherson P A, Perry C L et al.. The prevalence of reduced VWF survival phenotype (type 1C VWD) in type 1 index cases recruited into the TS Zimmerman Program for the Molecular and Clinical Biology of VWD (ZPMCB – VWD).  Blood. 2007;  110 2133 (a635)
    PubMedGoogle Scholar
  • 10 Eikenboom J, Van Marion V, Putter H et al.. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD.  J Thromb Haemost. 2006;  4 774-782
    CrossrefPubMedGoogle Scholar
  • 11 Casana P, Cabrera N, Haya S, Cid A R, Aznar J A. Von Willebrand's disease: a novel mutation, P1824H and the incidence of R1205H defect among families with dominant quantitative von Willebrand factor deficiency.  Haematologica. 2006;  91 1130-1133
    PubMedGoogle Scholar
  • 12 Bowen D J, Collins P W. An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13.  Blood. 2004;  103 941-947
    PubMedGoogle Scholar
  • 13 Cumming A, Grundy P, Keeney S et al.. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease.  Thromb Haemost. 2006;  96 630-641
    PubMedGoogle Scholar
  • 14 Goodeve A. Genetics of type 1 von Willebrand disease.  Curr Opin Hematol. 2007;  14 444-449
    CrossrefPubMedGoogle Scholar
  • 15 Flood V H, Kautza B C, Miller C A et al.. Common VWF haplotypes in normal African-Americans and Caucasians recruited into the ZPMCB-VWD and their impact on VWF laboratory testing.  Blood. 2007;  110 714 (a219)
    PubMedGoogle Scholar
  • 16 Casonato A, Sartorello F, Pontara E et al.. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.  Thromb Haemost. 2007;  98 1182-1187
    PubMedGoogle Scholar
  • 17 Eikenboom J C. Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology.  Best Pract Res Clin Haematol. 2001;  14 365-379
    CrossrefPubMedGoogle Scholar
  • 18 von Willebrand E A. Hereditary pseudohaemophilia.  Haemophilia. 1999;  5 223-231 discussion 222
    CrossrefPubMedGoogle Scholar
  • 19 Zhang Z P, Blomback M, Nyman D, Anvret M. Mutations of von Willebrand factor gene in families with von Willebrand disease in the Åland Islands.  Proc Natl Acad Sci U S A. 1993;  90 7937-7940
    CrossrefPubMedGoogle Scholar
  • 20 Baronciani L, Cozzi G, Canciani M T et al.. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients.  Blood Cells Mol Dis. 2003;  30 264-270
    CrossrefPubMedGoogle Scholar
  • 21 Ragni M V, Bontempo F A, Hassett A C. von Willebrand disease and bleeding in women.  Haemophilia. 1999;  5 313-317
    CrossrefPubMedGoogle Scholar
  • 22 James A H, Ragni M V, Picozzi V J. Bleeding disorders in premenopausal women: (another) public health crisis for hematology?.  Hematology Am Soc Hematol Educ Program. 2006;  474-485
    PubMedGoogle Scholar
  • 23 Sadler J E. Von Willebrand disease type 1: a diagnosis in search of a disease.  Blood. 2003;  101 2089-2093
    CrossrefPubMedGoogle Scholar
  • 24 Goldberg L, Ragni M. Bleeding score as a preoperative predictor of postoperative bleeding in type 1 von Willebrand disease.  Blood. 2006;  4394 , (303a)
    PubMedGoogle Scholar
  • 25 Federici A B, Castaman G, Thompson A, Berntorp E. Von Willebrand's disease: clinical management.  Haemophilia. 2006;  12(Suppl 3) 152-158
    CrossrefPubMedGoogle Scholar
  • 26 Tosetto A, Rodeghiero F, Castaman G et al.. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD).  J Thromb Haemost. 2006;  4 766-773
    CrossrefPubMedGoogle Scholar
  • 27 Tosetto A, Castaman G, Rodeghiero F. Assessing bleeding in von Willebrand disease with bleeding score.  Blood Rev. 2007;  21 89-97
    CrossrefPubMedGoogle Scholar
  • 28 Tosetto A, Castaman G, Rodeghiero F. Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach.  Blood. 2008;  111 3998-4003
    CrossrefPubMedGoogle Scholar
  • 29 Mannucci P M. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years.  Blood. 1997;  90 2515-2521
    PubMedGoogle Scholar
  • 30 Mannucci P M. Treatment of von Willebrand's disease.  N Engl J Med. 2004;  351 683-694
    CrossrefPubMedGoogle Scholar
  • 31 Petitti D B. Clinical practice. Combination estrogen-progestin oral contraceptives.  N Engl J Med. 2003;  349 1443-1450
    CrossrefPubMedGoogle Scholar
  • 32 Kadir R A, Lee C A, Sabin C A, Pollard D, Economides D L. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study.  Haemophilia. 2002;  8 787-793
    CrossrefPubMedGoogle Scholar
  • 33 Castaman G, Lethagen S, Federici A B et al.. Response to desmopressin is influenced by the genotype and phenotype in type 1 Von Willebrand Disease (VWD): results from the European study MCMDM-1VWD.  Blood. 2008;  111 3531-3539
    CrossrefPubMedGoogle Scholar
  • 34 Mannucci P M. Use of desmopressin (DDAVP) during early pregnancy in factor VIII-deficient women.  Blood. 2005;  105 3382
    PubMedGoogle Scholar
  • 35 Thompson A R, Gill J C, Ewenstein B M, Mueller-Velten G, Schwartz B A. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P).  Haemophilia. 2004;  10 42-51
    CrossrefPubMedGoogle Scholar
  • 36 Jankowitz R, Nichols T, Ragni M. Recombinant IL-11 (Neumega, rhIL-11) increases plasma von Willebrand factor in type 1 von Willebrand disease.  Blood. 2006;  108 1003 (299a)
    PubMedGoogle Scholar
  • 37 Denis C V, Kwack K, Saffaripour S et al.. Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models.  Blood. 2001;  97 465-472
    CrossrefPubMedGoogle Scholar
  • 38 Aydinok Y, Egemen A, Balkan C. Menorrhagia due to abnormalities of the platelet function: evaluation of two young patients.  Pediatr Int. 2007;  49 106-108
    CrossrefPubMedGoogle Scholar
  • 39 Rosenberg N, Lalezari S, Landau M, Shenkman B, Seligsohn U, Izraeli S. Trp207Gly in platelet glycoprotein Ib alpha is a novel mutation that disrupts the connection between the leucine-rich repeat domain and the disulfide loop structure and causes Bernard-Soulier syndrome.  J Thromb Haemost. 2007;  5 378-386
    CrossrefPubMedGoogle Scholar
  • 40 Kenny D, Morateck P A, Gill J C, Montgomery R R. The critical interaction of glycoprotein (GP) IB beta with GPIX-a genetic cause of Bernard-Soulier syndrome.  Blood. 1999;  93 2968-2975
    PubMedGoogle Scholar
  • 41 Miller J L. Platelet-type von Willebrand disease.  Thromb Haemost. 1996;  75 865-869
    PubMedGoogle Scholar
  • 42 Franchini M, Montagnana M, Lippi G. Clinical, laboratory and therapeutic aspects of platelet-type von Willebrand disease.  Int J Lab Hematol. 2008;  30 91-94
    CrossrefPubMedGoogle Scholar
  • 43 Takafuta T, Fujimura K, Shimomura T et al.. Precise diagnosis by gene analysis and successful management of delivery in three patients with type IIB von Willebrand disease.  Int J Hematol. 1994;  60 163-172
    PubMedGoogle Scholar
  • 44 Gohda F, Uchiumi H, Handa H et al.. Identification of inherited macrothrombocytopenias based on mean platelet volume among patients diagnosed with idiopathic thrombocytopenia.  Thromb Res. 2007;  119 741-746
    CrossrefPubMedGoogle Scholar
  • 45 Poon M-C. Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.  Vasc Health Risk Manag. 2007;  3 655-664
    PubMedGoogle Scholar
  • 46 Anwer A, Hanley J, Kumarendran K. Proposed management of pregnancy and labour in an inherited platelet disorder, Glanzmann's thrombasthenia.  J Obstet Gynaecol. 2007;  27 421-423
    CrossrefPubMedGoogle Scholar
  • 47 Poddar R K, Coley S, Pavord S. Hermansky-Pudlak syndrome in a pregnant patient.  Br J Anaesth. 2004;  93 740-742
    CrossrefPubMedGoogle Scholar
  • 48 Haldane J BS, Waddington C H. Inbreeding and linkage.  Genetics. 1931;  16 357-374
    PubMedGoogle Scholar
  • 49 Yang M Y, Ragni M V. Clinical manifestations and management of labor and delivery in women with factor IX deficiency.  Haemophilia. 2004;  10 483-490
    CrossrefPubMedGoogle Scholar
  • 50 Acquila M, Caprino D, Bicocchi P, Mori P G, Tagliaferri A R. A skewed lyonization phenomenon as cause of hemophilia A in a female patient.  Blood. 1995;  85 599-600
    PubMedGoogle Scholar
  • 51 Kadir R A, Economides D L, Braithwaite J, Goldman E, Lee C A. The obstetric experience of carriers of haemophilia.  Br J Obstet Gynaecol. 1997;  104 803-810
    PubMedGoogle Scholar
  • 52 Leissinger C, Becton D, Cornell Jr C, Cox Gill J. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A.  Haemophilia. 2001;  7 258-266
    CrossrefPubMedGoogle Scholar
  • 53 Gekas J, Broermann L, Heidenreich W. Outcome of pregnancy in patients with haemophilia B—two case reports.  Z Geburtshilfe Neonatol. 2007;  211 90-92
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 54 Shpilberg O, Peretz H, Zivelin A et al.. One of the two common mutations causing factor XI deficiency in Ashkenazi Jews (type II) is also prevalent in Iraqi Jews, who represent the ancient gene pool of Jews.  Blood. 1995;  85 429-432
    PubMedGoogle Scholar
  • 55 Ragni M V, Sinha D, Seaman F, Lewis J H, Spero J A, Walsh P N. Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds.  Blood. 1985;  65 719-724
    PubMedGoogle Scholar
  • 56 Bolton-Maggs P H. Bleeding problems in factor XI deficient women.  Haemophilia. 1999;  5 155-159
    CrossrefPubMedGoogle Scholar
  • 57 White B, Lawler P, Riddell A et al.. Response to desmopressin of factors XI, X and V in patients with factor VIII deficiency and von Willebrand disease.  Br J Haematol. 2004;  126 100-104
    CrossrefPubMedGoogle Scholar
  • 58 Franchini M, de Gironcoli M, Lippi G, Manzato F, Aprili G, Gandini G. Prophylactic use of desmopressin in surgery of six patients with symptomatic heterozygous factor XI deficiency.  Haematologica. 2000;  85 106-107
    PubMedGoogle Scholar
  • 59 Mavromatidis G, Dinas K, Delkos D et al.. Uneventful cesarean delivery with administration of factor XI concentrate in a patient with severe factor XI deficiency.  Int J Hematol. 2007;  86 222-224
    CrossrefPubMedGoogle Scholar
  • 60 Bern M M, Sahud M, Zhukov O, Qu K, Mitchell Jr W. Treatment of factor XI inhibitor using recombinant activated factor VIIa.  Haemophilia. 2005;  11 20-25
    CrossrefPubMedGoogle Scholar
  • 61 Peyvandi F, Jayandharan G, Chandy M et al.. Genetic diagnosis of haemophilia and other inherited bleeding disorders.  Haemophilia. 2006;  12(Suppl 3) 82-89
    PubMedGoogle Scholar
  • 62 Catanzarite V A, Novotny W F, Cousins L M, Schneider J M. Pregnancies in a patient with congenital absence of prothrombin activity: case report.  Am J Perinatol. 1997;  14 135-138
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 63 Girolami A, Scarano L, Saggiorato G, Girolami B, Bertomoro A, Marchiori A. Congenital deficiencies and abnormalities of prothrombin.  Blood Coagul Fibrinolysis. 1998;  9 557-569
    CrossrefPubMedGoogle Scholar
  • 64 Vellinga S, Steel E, Vangenechten I, Gadisseur A. Successful pregnancy in a patient with factor V deficiency: case report and review of the literature.  Thromb Haemost. 2006;  95 896-897
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 65 Girolami A, Scandellari R, Lombardi A M, Girolami B, Bortoletto E, Zanon E. Pregnancy and oral contraceptives in factor V deficiency: a study of 22 patients (five homozygotes and 17 heterozygotes) and review of the literature.  Haemophilia. 2005;  11 26-30
    PubMedGoogle Scholar
  • 66 D'Ambrosio R, Santacroce R, Di Perna P, Sarno M, Romondia A, Margaglione M. A new case of combined factor V and factor VIII deficiency further suggests that the LMAN1 M1T mutation is a frequent cause in Italian patients.  Blood Coagul Fibrinolysis. 2007;  18 203-204
    CrossrefPubMedGoogle Scholar
  • 67 Mohanty D, Ghosh K, Shetty S, Spreafico M, Garagiola I, Peyvandi F. Mutations in the MCFD2 gene and a novel mutation in the LMAN1 gene in Indian families with combined deficiency of factor V and VIII.  Am J Hematol. 2005;  79 262-266
    CrossrefPubMedGoogle Scholar
  • 68 Fregin A, Rost S, Wolz W, Krebsova A, Muller C R, Oldenburg J. Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16.  Blood. 2002;  100 3229-3232
    CrossrefPubMedGoogle Scholar
  • 69 Zhang B, Ginsburg D. Familial multiple coagulation factor deficiencies: new biologic insight from rare genetic bleeding disorders.  J Thromb Haemost. 2004;  2 1564-1572
    CrossrefPubMedGoogle Scholar
  • 70 Johnson D W, Berg J N, Gallione C J et al.. A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12.  Genome Res. 1995;  5 21-28
    CrossrefPubMedGoogle Scholar
  • 71 McAllister K A, Grogg K M, Johnson D W et al.. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1.  Nat Genet. 1994;  8 345-351
    CrossrefPubMedGoogle Scholar
  • 72 Lesca G, Olivieri C, Burnichon N et al.. Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network.  Genet Med. 2007;  9 14-22
    CrossrefPubMedGoogle Scholar
  • 73 Letteboer T G, Mager J J, Snijder R J et al.. Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia.  J Med Genet. 2006;  43 371-377
    PubMedGoogle Scholar
  • 74 Dahlgren L S, Effer S B, McGillivray B C, Pugash D J. Pregnancy with uterine vascular malformations associated with hemorrhagic hereditary telangiectasia: a case report.  J Obstet Gynaecol Can. 2006;  28 720-723
    PubMedGoogle Scholar
  • 75 Worda C, Lang I, Husslein P, Kneussl M. Hereditary hemorrhagic telangiectasia and pregnancy.  Obstet Gynecol. 2007;  110 474-477
    PubMedGoogle Scholar
  • 76 Cottin V, Chinet T, Lavole A et al.. Pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia: a series of 126 patients.  Medicine. 2007;  86 1-17
    CrossrefPubMedGoogle Scholar
  • 77 Pepin M, Schwarze U, Superti-Furga A, Byers P H. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type.  N Engl J Med. 2000;  342 673-680
    CrossrefPubMedGoogle Scholar
  • 78 Bjorck M, Pigg M, Kragsterman B, Bergqvist D. Fatal bleeding following delivery: a manifestation of the vascular type of Ehlers-Danlos' syndrome.  Gynecol Obstet Invest. 2007;  63 173-175
    CrossrefPubMedGoogle Scholar
  • 79 Volkov N, Nisenblat V, Ohel G, Gonen R. Ehlers-Danlos syndrome: insights on obstetric aspects.  Obstet Gynecol Surv. 2007;  62 51-57
    CrossrefPubMedGoogle Scholar
  • 80 Pallotta R, Ehresmann T, Fusilli P, De Paepe A, Nuytinck L. Discordance between phenotypic appearance and genotypic findings in a familial case of classical Ehlers-Danlos syndrome.  Am J Med Genet A. 2004;  128A 436-438
    CrossrefPubMedGoogle Scholar

Margaret V RagniM.D. M.P.H. 

Professor of Medicine, Department of Medicine, Division Hematology/Oncology, University of Pittsburgh School of Medicine, Director

Hemophilia Center of Western PA, 3636 Boulevard of the Allies, Pittsburgh, PA 15213-4306

eMail: ragni@dom.pitt.edu

      >